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Abstract
Postural instability and supranuclear gaze palsy represent the key symptoms of Richardson’s syndrome, the most
frequent clinical manifestation of progressive supranuclear palsy (PSP). However, a proportion of PSP patients never
develops ocular motor symptoms, which prevents clinicians from establishing the diagnosis during lifetime
according to current diagnostic criteria. We present one instructive autopsy-confirmed PSP case with prospective
video-documented clinical course, showing striking temporal divergence of initially present postural instability and
delayed development of ocular motor dysfunction. Brain imaging and autopsy findings were typical of PSP, but the
temporal sequence of symptoms was unusual with isolated postural instability predominating the clinical course for
many years and slowing of vertical saccades/supranuclear gaze palsy evolving not until the 9th/11th year after
disease onset. Although other differential diagnoses were unlikely, this patient did not pass the threshold for
possible or probable diagnosis of PSP according to current diagnostic criteria until very late in the disease course.
This first well documented, autopsy confirmed case of PSP with predominant postural instability further expands
the clinical spectrum of PSP and points out the need of new clinical diagnostic criteria with sufficient sensitivity
and specificity for an early and reliable diagnosis.
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Background
Progressive supranuclear palsy (PSP) is a disease entity
defined neuropathologically by aggregates of the
microtubule associated protein tau in astrocytes (tufted
astrocytes), neurons (neurofibrillary tangles) and oligoden-
drocytes (coiled bodies) in typical anatomical distribution
[1, 2]. Postural instability (PI) with falls, and slow vertical
saccades followed by supranuclear gaze palsy (SNGP)
represent the key symptoms of the typical clinical mani-
festation of PSP - termed Richardson’s syndrome (PSP-RS)
[3, 4]. The NINDS-SPSP criteria for the clinical diagnosis
of PSP require a combination of PI during the first year
and slowing of saccades or SNGP [5]. Proportions of
9–59 % of autopsy confirmed PSP patients have been
reported to never develop SNGP throughout the dis-
ease course [3, 6–9]. The causes for these variable and
high numbers remain unclear. Atypical clinical mani-
festations of PSP have been described, e.g. PSP with
initially predominant Parkinsonism (PSP-P), frontotem-
poral dysfunction (PSP-FTD), or akinesia with gait
freezing (PSP-PAGF), in which SNGP may indeed
evolve later in the disease course [10]. A recent retro-
spective study of N = 100 autopsy confirmed cases has
also suggested that as many as 18 % of PSP patients
may have an abortive development of PSP-RS, with PI
predominating the early clinical course and SNGP only
developing with major delay, coining the term PSP-PI.
The existence of PSP-PI cases has been questioned,
however, since an apparent lack of SNGP in retrospect-
ive series might result from insufficient examination or
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documentation of the actual clinical symptoms. Here,
we report the first prospectively video-documented
patient with progressive PI predominating the clinical
course for many years and very late onset of SNGP,
having confirmed PSP at autopsy, supporting the con-
cept of PSP-PI. This patient did not pass the threshold
for possible or probable PSP according to current diag-
nostic criteria until very late in the disease course [11].
Case presentation
The temporal evolution of symptoms is shown in Fig. 1a
and in the supplementary video (Additional file 1). At
67 years of age (in 1997), the initial symptoms occurred:
PI, pain of the left shoulder, hypokinesia of the left arm,
hypomimia and dysarthria. In the early disease course
the gait was minimally affected, it was slightly broad
based and slowing of turning was noted, the patient did
not require walking aids. The first falls occurred back-
wards in 2000, the patient had no gait ignition failure.
At first, Parkinson’s disease (PD) was suspected. After
5 years, atypical Parkinsonism was considered, since the
patient showed frequent falls and was non-responsive to
levodopa. The patient showed slight, but not pronounced
micrographia and hypohonia in the beginning of the
disease. Between year 5 and 10 after disease onset, the
patient developed mild limb rigidity, symmetric bradyki-
nesia, apraxia of both hands, freezing of gait and apathy.
Slowing of vertical saccades despite full range of voluntary
ocular movements in all directions was first observed in
the 9th year of his illness, vertical SNGP was only observed
in the 11th year (Fig. 1b and c, Additional file 1). Apart
from bilateral limb apraxia in the late course, the patient
did not show other signs of cortical sensory loss. The
patient’s condition worsened due to dysphagia and cogni-
tive decline in the 13th year of the disease. The patient
died of aspiration pneumonia after an exceptionally long
disease duration of 15 years at the age of 82.
Brain imaging
Single photon emission computed tomography (SPECT)
with 123J-FP-CIT in the 8th year revealed bilaterally
reduced striatal dopamine transporter density. Magnetic
resonance imaging (MRI) showed predominant atrophy
of the midbrain tegmentum (anteroposterior midbrain
diameter of 11.9 mm after 12 years and 11.6 mm after
14 years) with enlarged ventricular spaces, moderate
prefrontal atrophy and discrete vascular lesions (Fig. 1d).
The midbrain-to-pons-ratio was 0.49 [12].
Autopsy findings
Although the temporal evolution of symptoms was
unusual, brain autopsy findings revealed typical neuro-
pathological features of PSP: Macroscopically, slight fron-
totemporal and severe midbrain atrophy was observed,
furthermore dilated lateral ventricles. While substantia
nigra, dentate nucleus (cerebellum), locus coeruleus and
medulla oblongata exhibited pronounced neurodegenera-
tive changes (neuronal loss and gliosis) on haematoxylin-
eosin-histology, globus pallidus showed only discrete
neurodegenerative changes. Tau immunostaining demon-
strated widespread tau deposits in tufted astrocytes (TA),
coiled bodies (CB), neurofibrillary tangles (NFT) and
neuropil threads (NT) in frontal cortex, striatum, insula,
basal ganglia, amygdala, hippocampus, midbrain and pons.
Thus, the neuropathologic criteria for PSP were clearly
fulfilled (Fig. 1e) [2]. The tau distribution fits into score 4-
5 according to the scale presented by Williams with more
severe involvement of the basal ganglia and dentate
nucleus with involvement of the frontal and parietal lobes
[13]. Tufted astrocytes were mainly found in the caudate
Fig. 1 Case presentation. a Timeline of the evolution of clinical
symptoms. b and c Demonstration of absent supranuclear gaze palsy
(SNGP) despite clear postural instability (PI) in the 9th year after
symptom onset. d MRI showing predominant midbrain atrophy in the
13th year after symptom onset. e Representative histopathological
section (pallidum) showing the typical histopathological hallmarks of
PSP), i.e. tufted astrocytes (TA), coiled bodies (CB), neurofibrillary
tangles (NFT) and neuropil threads (NT) (Gallyas silver stain). f
Histopathological section (globus pallidus) with loss of neurons,
intracytoplasmic inclusions and gliosis (Hematoxilin-Eosin staining). g
Tufted astrocytes in striatum (globus pallidus) as the neuropathological
hallmark of PSP (Gallyas silver stain)
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nucleus (severe) and frontal cortex (moderate) and trans-
entorhinal cortex (moderate). The following concomitant
neurodegenerative pathologies were observed: widespread
beta amyloid deposits (stage 5) [14], cerebral amyloid
angiopathy (1 type 2) [15], Alzheimer’s disease (Braak and
Braak stage 3) [16] and argyrophilic grain disease (stage 3)
[17]. The “ABC” score for AD neuropathologic changes in
this case was A3 B2 C2 [18]. TDP43 positive deposits were
not detected in the following brain regions: frontal cortex,
striatum, hippocampus and amygdala, caudal medulla and
cerebellum.
Conclusions
While SNGP was initially described, and is still consid-
ered as the most specific clinical hallmark of PSP, coin-
ing the disease’s name, we present to our knowledge the
first prospectively video-documented and autopsy-
confirmed PSP patient with an unexpected long latency
of 11 years between the clinical disease onset with ini-
tially predominant PI and late development of SNGP.
This patient provides clear evidence for the concept that
a subgroup of definite PSP does indeed present with a
clinical predominance type of PSP-PI [5]. We carefully
considered the possibility of this case representing a
variant of pure akinesia with gait freezing (PAGF), which
is considered to be one of the phenotypic presentations
of pallido-nigro-luysial atrophy (PNLA), a rare variant of
PSP [19, 20]. The long disease duration of 15 years and
the late onset of SNGP fit the prior descriptions of
PNLA/PSP-PAGF [20]. However, early onset of falls, late
onset of freezing of gait and an advanced age at disease
onset (67 years) compared to the previously reported
PNLA/PSP-PAGF cases rendered this possibility unlikely
[19]. Moreover, as mentioned above, this case clearly
fulfilled the diagnostic criteria of PSP - high density of
neurofibrillary tangles (NFT) and neuropil threads (NT)
in three out of four cardinal nuclei: substantia nigra,
globus pallidus and pons and a moderate-to-high dens-
ity of NFT and NT three out of four of secondary areas
(striatum, oculomotor complex and dentate nucleus of
cerebellum) -and did not resemble the distribution of
pathological changes in PNLA/PSP-PAGF [2, 11, 19, 20].
Clinical differential diagnosis
As hypokinesia in the left upper limb and hypomimia
had initially been present, the diagnosis of PD had first
been suggested. This diagnosis was questionable right
from the beginning, since prominent PI was among the
patient’s initial complaints, which does not develop until
late into the disease in typical PD. Furthermore, tremor,
present in many patients with PD and some patients
with PSP-P was absent in this patient throughout the
clinical course. The clear lack of response to levodopa
therapy despite evidence for presynaptic dopaminergic
degeneration by SPECT imaging suggested postsynaptic
dopaminoceptive dysfunction in this patient and affirmed
the doubt at the diagnosis of PD [9, 21, 22]. There was no
reason to suggest multiple system atrophy (MSA) because
ataxia and autonomic dysfunction were absent [9, 22]. A
corticobasal syndrome (CBS) might have been considered
by year 9, since apraxic features occurred in both hands.
However, neither dystonia, myoclonus, nor alien limb
phenomenon as additional cortical features were present,
the motor signs were strikingly symmetric by then, and
the average survival time of CBS patient (7.9 years) had
passed by far at this time, rendering the diagnosis of CBS
unlikely [9, 21, 23]. Brain imaging did not show vascular
lesions of the basal ganglia and brainstem suggestive of
vascular parkinsonism. Slowing of vertical saccades
allowed the diagnosis of possible PSP according to the
NINDS-SPSP criteria in the 9th year of his illness. With
development of vertical SNGP, the patient fulfilled the
criteria for probable PSP in the 11th year [5]. Cognitive
changes typically observed in PSP, including apathy and
reduced verbal fluency were not observed until 10 years
after onset in this patient [21, 24]. Predominant mesen-
cephalic atrophy clearly below the threshold suggestive of
PSP [25] has been demonstrated by MRI in the 12th year
Since data from prior MRI is not available, it cannot be
verified if structural imaging had allowed to suggest PSP
at an earlier time point than the clinical features. As
typical for PSP, the patient developed dysphagia in the
terminal phase and died of aspiration pneumonia. Com-
pared to the average disease duration of PSP (8.7 years)
[10], the patient experienced an exceptionally long disease
duration of 15 years, but individual cases with survival as
long as 16 years have been previously reported [3].
In summary, this clinically well documented case
strengthens the concept that individual patients with
definite PSP can present with predominant progres-
sive PI (PSP-PI predominance type), as it had been
previously proposed on the basis of a retrospective
case series. This observation further expands the clin-
ical spectrum of definite PSP and underlines the need
to adapt the clinical diagnostic criteria to allow diag-
nosing syndromes suggestive for PSP, such as PSP-PI,
as early as possible.
Additional file
Additional file 1: Video-documented clinical course of an autopsy-
confirmed PSP patient with predominant postural instability (PSP-PI) and
very late onset of ocular motor dysfunction. In 1997, the initial symptoms
occurred at the age of 67. The patient was filmed three times. In 2005
(9th year after onset) postural instability and freezing of gait was observed.
In 2006 (10th year after onset) gait became further unstable despite full
range of voluntary ocular movements. In 2009 (13th year after onset) the
patient showed supranuclear gaze palsy, apraxia of eye-lid opening and
cognitive decline. (MP4 12617 kb)
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